Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis

Jason D. Theis, Surendra Dasari, Julie A. Vrana, Paul J. Kurtin, Ahmet Dogan

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using shotgun proteomics for routine diagnostics. In this perspectives article, we describe the clinical implementation of a shotgun proteomics assay for amyloid subtyping, with a special emphasis on standardizing the platform for better quality control and earning clinical acceptance. This assay is the first shotgun proteomics assay to receive regulatory approval for patient diagnosis. The blueprint of this assay can be utilized to develop novel proteomics assays for detecting numerous other disease pathologies.

Original languageEnglish (US)
Pages (from-to)1067-1077
Number of pages11
JournalJournal of Mass Spectrometry
Volume48
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Assays
Clinical laboratories
Testing
Blueprints
Pathology
Research laboratories
Amyloid
Quality control
Proteomics
Antibodies

Keywords

  • amyloidosis
  • clinical
  • diagnostic test
  • mutant protein
  • proteomics
  • spectrometry
  • tandem mass

ASJC Scopus subject areas

  • Spectroscopy

Cite this

Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. / Theis, Jason D.; Dasari, Surendra; Vrana, Julie A.; Kurtin, Paul J.; Dogan, Ahmet.

In: Journal of Mass Spectrometry, Vol. 48, No. 10, 10.2013, p. 1067-1077.

Research output: Contribution to journalArticle

Theis, Jason D. ; Dasari, Surendra ; Vrana, Julie A. ; Kurtin, Paul J. ; Dogan, Ahmet. / Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. In: Journal of Mass Spectrometry. 2013 ; Vol. 48, No. 10. pp. 1067-1077.
@article{30fd59a8812d47f9bf1035a8b3b54d92,
title = "Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis",
abstract = "Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using shotgun proteomics for routine diagnostics. In this perspectives article, we describe the clinical implementation of a shotgun proteomics assay for amyloid subtyping, with a special emphasis on standardizing the platform for better quality control and earning clinical acceptance. This assay is the first shotgun proteomics assay to receive regulatory approval for patient diagnosis. The blueprint of this assay can be utilized to develop novel proteomics assays for detecting numerous other disease pathologies.",
keywords = "amyloidosis, clinical, diagnostic test, mutant protein, proteomics, spectrometry, tandem mass",
author = "Theis, {Jason D.} and Surendra Dasari and Vrana, {Julie A.} and Kurtin, {Paul J.} and Ahmet Dogan",
year = "2013",
month = "10",
doi = "10.1002/jms.3264",
language = "English (US)",
volume = "48",
pages = "1067--1077",
journal = "Journal of Mass Spectrometry",
issn = "1076-5174",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis

AU - Theis, Jason D.

AU - Dasari, Surendra

AU - Vrana, Julie A.

AU - Kurtin, Paul J.

AU - Dogan, Ahmet

PY - 2013/10

Y1 - 2013/10

N2 - Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using shotgun proteomics for routine diagnostics. In this perspectives article, we describe the clinical implementation of a shotgun proteomics assay for amyloid subtyping, with a special emphasis on standardizing the platform for better quality control and earning clinical acceptance. This assay is the first shotgun proteomics assay to receive regulatory approval for patient diagnosis. The blueprint of this assay can be utilized to develop novel proteomics assays for detecting numerous other disease pathologies.

AB - Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using shotgun proteomics for routine diagnostics. In this perspectives article, we describe the clinical implementation of a shotgun proteomics assay for amyloid subtyping, with a special emphasis on standardizing the platform for better quality control and earning clinical acceptance. This assay is the first shotgun proteomics assay to receive regulatory approval for patient diagnosis. The blueprint of this assay can be utilized to develop novel proteomics assays for detecting numerous other disease pathologies.

KW - amyloidosis

KW - clinical

KW - diagnostic test

KW - mutant protein

KW - proteomics

KW - spectrometry

KW - tandem mass

UR - http://www.scopus.com/inward/record.url?scp=84885573368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885573368&partnerID=8YFLogxK

U2 - 10.1002/jms.3264

DO - 10.1002/jms.3264

M3 - Article

VL - 48

SP - 1067

EP - 1077

JO - Journal of Mass Spectrometry

JF - Journal of Mass Spectrometry

SN - 1076-5174

IS - 10

ER -